Anders Själander

3.7k total citations
81 papers, 1.9k citations indexed

About

Anders Själander is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Hematology. According to data from OpenAlex, Anders Själander has authored 81 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Cardiology and Cardiovascular Medicine, 23 papers in Internal Medicine and 16 papers in Hematology. Recurrent topics in Anders Själander's work include Atrial Fibrillation Management and Outcomes (46 papers), Venous Thromboembolism Diagnosis and Management (23 papers) and Cardiac Arrhythmias and Treatments (22 papers). Anders Själander is often cited by papers focused on Atrial Fibrillation Management and Outcomes (46 papers), Venous Thromboembolism Diagnosis and Management (23 papers) and Cardiac Arrhythmias and Treatments (22 papers). Anders Själander collaborates with scholars based in Sweden, United Kingdom and France. Anders Själander's co-authors include Peter J. Svensson, Henrik Renlund, G. Beckman, Peter J Svensson, Richard Birgander, Mattias Wieloch, Niclas Eriksson, Mårten Rosenqvist, L. Beckman and L. Athlin and has published in prestigious journals such as Circulation, Blood and Annals of Internal Medicine.

In The Last Decade

Anders Själander

74 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anders Själander Sweden 24 991 491 452 322 307 81 1.9k
Sergio Siragusa Italy 26 595 0.6× 748 1.5× 242 0.5× 960 3.0× 360 1.2× 150 2.1k
Laura Russo Italy 22 350 0.4× 652 1.3× 261 0.6× 575 1.8× 399 1.3× 56 1.7k
Andrés J. Muñoz Martín Spain 20 906 0.9× 1.2k 2.5× 551 1.2× 191 0.6× 145 0.5× 131 2.0k
Avi Leader Israel 20 357 0.4× 321 0.7× 365 0.8× 336 1.0× 130 0.4× 89 1.2k
Eduardo Rocha Spain 27 584 0.6× 688 1.4× 152 0.3× 757 2.4× 154 0.5× 108 2.0k
Xiaolei Zhu China 14 625 0.6× 235 0.5× 830 1.8× 156 0.5× 604 2.0× 35 2.1k
Gregory C. Connolly United States 21 687 0.7× 1.2k 2.5× 389 0.9× 269 0.8× 135 0.4× 31 1.8k
Jeannine Kassis Canada 25 868 0.9× 1.5k 3.1× 206 0.5× 756 2.3× 337 1.1× 64 2.6k
Chris E. Holmes United States 19 244 0.2× 365 0.7× 782 1.7× 351 1.1× 420 1.4× 58 1.8k
Kristen M. Sanfilippo United States 19 288 0.3× 477 1.0× 311 0.7× 395 1.2× 140 0.5× 101 1.2k

Countries citing papers authored by Anders Själander

Since Specialization
Citations

This map shows the geographic impact of Anders Själander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Själander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Själander more than expected).

Fields of papers citing papers by Anders Själander

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anders Själander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Själander. The network helps show where Anders Själander may publish in the future.

Co-authorship network of co-authors of Anders Själander

This figure shows the co-authorship network connecting the top 25 collaborators of Anders Själander. A scholar is included among the top collaborators of Anders Själander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anders Själander. Anders Själander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hijazi, Ziad, Lars Wallentin, Håkan Arheden, et al.. (2025). Rationale and design of a registry-based randomized controlled study of personalized biomarker-based risk score-guided stroke prevention treatment in atrial fibrillation. American Heart Journal. 290. 161–169. 1 indexed citations
2.
3.
Stefansson, Kristina, et al.. (2025). Exploring the extent of post-analytical errors, with a focus on transcription errors – an intervention within the VIPVIZA study. Clinical Chemistry and Laboratory Medicine (CCLM). 63(8). 1555–1560.
4.
Renlund, Henrik, et al.. (2024). Risk factors for major bleeding in patients with atrial fibrillation and CKD G3–G5D on oral anticoagulants. Clinical Kidney Journal. 17(8). sfae206–sfae206. 1 indexed citations
5.
Renlund, Henrik, et al.. (2023). Warfarin treatment quality and outcomes in patients with non-valvular atrial fibrillation and CKD G3-G5D. Thrombosis Research. 229. 131–138. 2 indexed citations
6.
Gummesson, Christina, Mattias Ekstedt, Jarl Hellman, et al.. (2023). Entrustable professional activities (EPAs) for undergraduate medical education – development and exploration of social validity. BMC Medical Education. 23(1). 635–635. 11 indexed citations
7.
Lilja, Johan, et al.. (2023). Prevalence of atrial fibrillation and reasons for undertreatment with oral anticoagulants. Journal of Thrombosis and Thrombolysis. 57(1). 101–106. 1 indexed citations
8.
Andréasson, Björn, et al.. (2023). Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event—A population based cohort study. European Journal Of Haematology. 110(6). 608–617. 2 indexed citations
9.
Själander, Anders, et al.. (2023). Direct oral anticoagulants: patient reported adherence and minor bleedings. Journal of Thrombosis and Thrombolysis. 56(1). 55–64. 2 indexed citations
10.
Dahlén, Torsten, Gustaf Edgren, Per Ljungman, et al.. (2022). Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study. American Journal of Hematology. 97(4). 421–430. 8 indexed citations
11.
Själander, Anders, et al.. (2018). Predictors for INR-control in a well-managed warfarin treatment setting. Journal of Thrombosis and Thrombolysis. 47(2). 227–232. 12 indexed citations
12.
13.
Norrving, Bo, et al.. (2016). Abstract 18795: Non-Vitamin K Oral Anticoagulants Are Non-Inferior for Stroke Prevention but Cause Fewer Major Bleedings Than Well-Managed Warfarin With Time in Therapeutic Range 70% or Higher in Sweden. Circulation. 1 indexed citations
14.
Svensson, Peter J., et al.. (2016). Venous thromboembolism and cancer risk. Journal of Thrombosis and Thrombolysis. 43(1). 68–73. 27 indexed citations
15.
Renlund, Henrik, et al.. (2015). Warfarin treatment complications do not correlate to cTTR when above 70%. Thrombosis Research. 136(6). 1185–1189. 7 indexed citations
16.
Själander, Anders, et al.. (2015). INR variability and outcomes in patients with mechanical heart valve prosthesis. Thrombosis Research. 136(6). 1211–1215. 13 indexed citations
17.
Själander, Anders, et al.. (2013). Atrial fibrillation patients do not benefit from acetylsalicylic acid. EP Europace. 16(5). 631–638. 59 indexed citations
18.
Rosenqvist, Mårten, et al.. (2012). Computerised assistance for warfarin dosage — Effects on treatment quality. European Journal of Internal Medicine. 23(8). 742–744. 17 indexed citations
19.
Själander, Anders, Jan-Håkan Jansson, David Bergqvist, et al.. (2007). Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta‐analysis. Journal of Internal Medicine. 263(1). 52–60. 47 indexed citations
20.
Själander, Anders, Richard Birgander, Narayan Chandra Saha, L. Beckman, & G. Beckman. (1996). p53 Polymorphisms and Haplotypes Show Distinct Differences between Major Ethnic Groups. Human Heredity. 46(1). 41–48. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sergio Siragusa Breakdown of academic impact, for papers by Laura Russo Breakdown of academic impact, for papers by Andrés J. Muñoz Martín Breakdown of academic impact, for papers by Avi Leader Breakdown of academic impact, for papers by Eduardo Rocha Breakdown of academic impact, for papers by Xiaolei Zhu Breakdown of academic impact, for papers by Gregory C. Connolly Breakdown of academic impact, for papers by Jeannine Kassis Breakdown of academic impact, for papers by Chris E. Holmes Breakdown of academic impact, for papers by Kristen M. Sanfilippo
Rankless by CCL
2026